DBV Technologies (DBVT) Common Equity (2015 - 2026)
DBV Technologies (DBVT) posted quarterly Common Equity of $160.4 million for Q2 2026, up 86.08% year-on-year from $86.2 million in Q2 2025, and down 22.85% on a QoQ basis from $207.9 million in Q1 2026.
DBV Technologies (DBVT) Common Equity (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Common Equity for 12 consecutive years, with $160.4 million the latest figure, recorded in Q2 2026.
- Quarterly Common Equity rose 86.08% year-over-year to $160.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $160.4 million (up 86.08% YoY) and the FY2025 annual result came in at $168.8 million, up 516.06% from the prior year.
- Common Equity retreated to $160.4 million in Q2 2026 per DBVT's latest filing, from $207.9 million in the prior quarter.
- Over the last five years, Common Equity for DBVT reached as high as $244.4 million in Q2 2022 and fell as low as $2.9 million in Q1 2025.
- A 5-year average of $128.4 million and a median of $142.1 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 97.4% — and 2026, when it surged 7068.97%.
- Year by year, Common Equity stood at $194.5 million in 2022, then slipped by 27.91% to $140.2 million in 2023, then slumped by 80.45% to $27.4 million in 2024, then jumped by 516.06% to $168.8 million in 2025, then slipped by 4.98% to $160.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $160.4 million, $207.9 million, and $168.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 160.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.40 Mn |
| Mar 31, 2026 | 207.90 Mn |
| Dec 31, 2025 | 168.80 Mn |
| Sep 30, 2025 | 52.85 Mn |
| Jun 30, 2025 | 86.20 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 27.40 Mn |
| Sep 30, 2024 | 54.03 Mn |
| Jun 30, 2024 | 79.10 Mn |
| Mar 31, 2024 | 111.65 Mn |
| Dec 31, 2023 | 140.19 Mn |
| Sep 30, 2023 | 143.99 Mn |
| Jun 30, 2023 | 164.24 Mn |
| Mar 31, 2023 | 179.09 Mn |
| Dec 31, 2022 | 194.45 Mn |
| Sep 30, 2022 | 212.05 Mn |
| Jun 30, 2022 | 244.42 Mn |
| Mar 31, 2022 | 82.06 Mn |
| Dec 31, 2021 | 99.27 Mn |
| Sep 30, 2021 | 116.89 Mn |